CoChat

Practice Guidelines for the Treatment of Candidiasis

The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.

Abstract

Infections due to Candida species are the most common of the fungal infections. Candida species produce a broad range of infections, ranging from non-life-threatening mucocutaneous illnesses to invasive process that may involve virtually any organ. Such a broad range of infections requires an equally broad range of diagnostic and therapeutic strategies. This document summarizes current knowledge about treatment of multiple forms of candidiasis and is the guideline of the Infectious Diseases Society of America (IDSA) for the treatment of candidiasis. Throughout this document, treatment recommendations are scored according to the standard scoring scheme used in other IDSA guidelines to illustrate the strength of the underlying data. The document covers 4 major topical areas. The role of the microbiology laboratory. To a greater extent than for other fungi, treatment of candidiasis can now be guided by in vitro susceptibility testing. The guidelines review the available information supporting current testing procedures and interpretive breakpoints and place these data into clinical context. Susceptibility testing is most helpful in dealing with infection due to non-albicans species of Candida. In this setting, especially if the patient has been treated previously with an azole antifungal agent, the possibility of microbiological resistance must be considered. Treatment of invasive candidiasis. In addition to acute hematogenous candidiasis, the guidelines review strategies for treatment of 15 other forms of invasive candidiasis. Extensive data from randomized trials are really available only for therapy of acute hematogenous candidiasis in the nonneutropenic adult. Choice of therapy for other forms of candidiasis is based on case series and anecdotal reports. In general, both amphotericin B and the azoles have a role to play in treatment. Choice of therapy is guided by weighing the greater activity of amphotericin B for some non-albicans species (e.g., Candida krusei) against the lesser toxicity and ease of administration of the azole antifungal agents. Flucytosine has activity against many isolates of Candida but is not often used. Treatment of mucocutaneous candidiasis. Therapy for mucosal infections is dominated by the azole antifungal agents. These drugs may be used topically or systemically and have been proven safe and efficacious. A significant problem with mucosal disease is the propensity for a small proportion of patients to suffer repeated relapses. In some situations, the explanation for such a relapse is obvious (e.g., relapsing oropharyngeal candidiasis in an individual with advanced and uncontrolled HIV infection), but in other patients the cause is cryptic (e.g., relapsing vaginitis in a healthy woman). Rational strategies for these situations are discussed in the guidelines and must consider the possibility of induction of resistance over time. Prevention of invasive candidiasis. Prophylactic strategies are useful if the risk of a target disease is sharply elevated in a readily identified group of patients. Selected patient groups undergoing therapy that produces prolonged neutropenia (e.g., some bone-marrow transplant recipients) or who receive a solid-organ transplant (e.g., some liver transplant recipients) have a sufficient risk of invasive candidiasis to warrant prophylaxis. Relationship between epidemiology of candidal infections and therapy. Although Candida albicans remains the most common pathogen in oropharyngeal and cutaneous candidiasis, non-albicans species of Candida are increasingly frequent problems in both invasive candidiasis [1] and vaginal candidiasis [2]. This is particularly problematic in patients with acutely life-threatening invasive candidal infections. Although the susceptibility of Candida to the currently available antifungal agents can be predicted if the species of the infecting isolate is known (table 1) [1, 3–13], individual isolates do not necessarily follow the general pattern. For example, C. albicans is usually susceptible to all major agents. However, azole resistance for this species is now well described among HIV-infected individuals with relapsing oropharyngeal candidiasis and is also reported sporadically in critically ill adults with invasive candidiasis [14]. For this reason, susceptibility testing for azole resistance is increasingly important in the management of candidiasis in patients. On the other hand, most Candida isolates appear to remain susceptible to amphotericin B, although recent data suggest that isolates of Candida glabrata and C. krusei may require maximal doses of amphotericin B (see below). General patterns of susceptibility of Candida species. Susceptibility testing and drug dosing. Intensive efforts to develop standardized, reproducible, and clinically relevant susceptibility testing methods for the fungi have resulted in the of the for susceptibility testing of interpretive breakpoints this are available for testing the susceptib

Overview

Integrity signals

Registry

Crossref · 10.1086/313749

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 185 references

Research works printed but not linked: 26

  1. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/177.2.425 · doi:10.1093/jnlids/177.2.425
  2. 1998, Clinical Infectious Diseases, 27, 981
  3. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/168.5.1311 · doi:10.1093/jnlids/168.5.1311
  4. 1998, Clinical Infectious Diseases, 27, 938
  5. 1999, Antimicrobial Agents and Chemotherapy, 43, 1289, 10.1128/AAC.43.5.1289 · DOI · Paper page
  6. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/173.5.1208 · doi:10.1093/jnlids/173.5.1208
  7. 1998, Medical mycology : official publication of the International Society for Human and Animal Mycology, 36, 156
  8. THALER, 1988, Annals of Internal Medicine, 108, 88, 10.1059/0003-4819-108-1-88 · doi:10.1059/0003-4819-108-1-88
  9. 1995, 76, 2357, 10.1002/1097-0142(19951201)76:11<2357::AID-CNCR2820761126>3.0.CO;2-H · doi:10.1002/1097-0142(19951201)76:11<2357::aid-cncr2820761126>3.0.co;2-h
  10. 1991, Clinical orthopaedics and related research, 267, 174
  11. Solomkin, 1980, Surgery, 88, 524
  12. MEYERS, 1973, Annals of Internal Medicine, 79, 647, 10.1059/0003-4819-79-5-647 · doi:10.1059/0003-4819-79-5-647
  13. Pons, 1993, Journal of acquired immune deficiency syndromes, 6, 1311
  14. Bonacini, 1991, Archives of Internal Medicine, 151, 1567, 10.1001/archinte.1991.00400080067012 · doi:10.1001/archinte.1991.00400080067012 · Paper page
  15. Bhatia, 1989, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 8, 171
  16. 1996, 110, 1803
  17. Laine, 1992, Annals of Internal Medicine, 117, 655, 10.1059/0003-4819-117-8-655 · doi:10.1059/0003-4819-117-8-655
  18. 1996, 111, 1169
  19. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/176.1.227 · doi:10.1093/jnlids/176.1.227
  20. 1994, 107, 744
  21. De Doncker, 1995, Cutis; cutaneous medicine for the practitioner, 56, 180
  22. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/171.6.1545 · doi:10.1093/jnlids/171.6.1545
  23. 1994, Transactions of the American Clinical and Climatological Association, 106, 38
  24. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/170.3.644 · doi:10.1093/jnlids/170.3.644
  25. 1995, Lancet, 349, 1234
  26. Benedetti, 1996, Journal of the American College of Surgeons, 183, 307

Cited by

Metadata

Authors
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E.
Affiliations
  • Texas Medical Center (US)
  • National Cancer Institute (US)
  • Wayne State University (US)
  • Harbor–UCLA Medical Center (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Rex, J. H.
Venue
Clinical Infectious Diseases
Published
2000-04-01
Volume
30
Issue
4
Pages
662-678
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2143449612
Cited by
927
References
185
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 12 · 2015: 13 · 2014: 24 · 2013: 20 · 2012: 47
FWCI
66.22
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
candidiasis, Candida, invasive candidiasis, mucocutaneous candidiasis, oropharyngeal candidiasis, vaginal candidiasis, candidiasis treatment, antifungal agents, amphotericin B, azole antifungals, 5-fluorocytosine, antifungal susceptibility testing, non-albicans Candida, Candida krusei, relapse, neutropenia, HIV infection, treatment guidelines, interpretive breakpoints
MeSH terms
Adult, Amphotericin B, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cost-Benefit Analysis, Female, Fever, Humans, Microbial Sensitivity Tests, Neutropenia, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.